Literature DB >> 15566813

Application of fluoroimmunoassay to the identification of low avidity specific IgG against pathogenic human viruses and Toxoplasma gondii.

F de Ory1, I Casas, C J Domingo, J Echevarría.   

Abstract

BACKGROUND: Serological diagnosis of primary viral infections is usually made by detection of specific IgM. In some cases, false positive results (mainly due to crossreactions between closely related viruses) can be obtained. Moreover, some primary infections occur without specific IgM response. Thus, alternative serological approaches are required for diagnosis. Detection of low avidity, specific IgG has been applied as a useful serological marker for diagnosing infections caused by several viruses and Toxoplasma gondii.
OBJECTIVE: The standardization and application of specific IgG avidity assays using a semiautomated solid phase immunoassay (fluoroimmunoassay (FIA)) on the basis of the urea elution principle, for the characterization of low avidity specific IgG against rubella virus, herpes simplex virus (HSV), varicella-zoster virus (VZV), cytomegalovirus (CMV) and T. gondii. STUDY
DESIGN: The method consists of two simultaneous determinations, one as recommended by the manufacturer and the other including a washing step with 8 M urea after the antigen-antibody reaction. A reduction in titer higher than, or equal to, 50% was considered indicative for presence of low avidity specific IgG.
RESULTS: When applied to the diagnosis of infections, this method showed sensitivity ranging from 81% to 100%, and absolute specificity. The detection of low avidity specific IgG allowed the differentiation between primary and recurrent infections caused by VZV. Furthermore, it helped in the identification of CMV as the etiological agent of congenital infection in the absence of specific IgM response, as well as in the elucidation of crossreactivity between antigenically related viruses, i.e., VZV and HSV, and Epstein-Barr virus and CMV.
CONCLUSION: FIA can be used for the characterization of the avidity of specific IgG antibody as a diagnostic test in clinical laboratories.

Entities:  

Year:  1995        PMID: 15566813     DOI: 10.1016/0928-0197(94)00045-v

Source DB:  PubMed          Journal:  Clin Diagn Virol        ISSN: 0928-0197


  7 in total

1.  A new method with general diagnostic utility for the calculation of immunoglobulin G avidity.

Authors:  M H Korhonen; J Brunstein; H Haario; A Katnikov; R Rescaldani; K Hedman
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

2.  Reliability of low-avidity IgG and of IgA in the diagnosis of primary infection by rubella virus with adaptation of a commercial test.

Authors:  J Gutiérrez; M J Rodríguez; F De Ory; G Piédrola; M C Maroto
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

3.  Reliability of four methods for the diagnosis of acute infection by Epstein-Barr virus.

Authors:  J Gutiérrez; M Rodríguez; C Maroto; G Piédrola
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

4.  Comparison of commercial methods of immunoblot, ELISA, and chemiluminescent immunoassay for detecting type-specific herpes simplex viruses-1 and -2 IgG.

Authors:  Fernando de Ory; María-Eulalia Guisasola; Pilar Balfagón; Juan Carlos Sanz
Journal:  J Clin Lab Anal       Date:  2017-03-23       Impact factor: 2.352

Review 5.  Delayed maturation of immunoglobulin G avidity: implication for the diagnosis of toxoplasmosis in pregnant women.

Authors:  M Lefevre-Pettazzoni; S Le Cam; M Wallon; F Peyron
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-11       Impact factor: 3.267

6.  ABO, D blood typing and subtyping using plug-based microfluidics.

Authors:  Timothy R Kline; Matthew K Runyon; Mohammad Pothiawala; Rustem F Ismagilov
Journal:  Anal Chem       Date:  2008-07-23       Impact factor: 6.986

Review 7.  Diagnosis of toxoplasmosis and typing of Toxoplasma gondii.

Authors:  Quan Liu; Ze-Dong Wang; Si-Yang Huang; Xing-Quan Zhu
Journal:  Parasit Vectors       Date:  2015-05-28       Impact factor: 3.876

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.